Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.

Abstract

This study demonstrates increased anthracycline-related cardiomyopathy risk at doses as low as 101 to 150 mg/m(2). Homozygosis for G allele in CBR3 contributes to increased cardiomyopathy risk associated with low- to moderate-dose anthracyclines, such that there seems to be no safe dose for patients homozygous for the CBR3 V244M G allele.

These results suggest a need for targeted intervention for those at increased risk of cardiomyopathy.

Full Text

• DOI - Journal of clinical oncology : official journal of the American Society of Clinical Oncology (DOI)
• HighWire Press - full-text online
• EBSCO - full-text online

Subjects

• Adolescent
• Age Factors
• Alcohol Oxidoreductases
• Anthracyclines
• Antibiotics, Antineoplastic
• Biotransformation
• Cardiomyopathies
• Case-Control Studies
• Chi-Square Distribution
• Child
• Child, Preschool
• Dose-Response Relationship, Drug
• Female
• Genetic Predisposition to Disease
• Homozygote
• Humans
• Infant
• Infant, Newborn
• Logistic Models
• Male
• Neoplasms
• Odds Ratio
• Pharmacogenetics
• Phenotype
• Polymorphism, Single Nucleotide
• Risk Assessment
• Risk Factors
• Survivors
• Time Factors
• United States
• Young Adult

Similar articles

• Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography. (2001-10-31)
• Heart transplant survival outcomes for adriamycin-dilated cardiomyopathy. (2012-11-27)
• Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. (2008-06-10)
• Anthracycline-based chemotherapy in metastatic endometrial carcinoma: An update. (2012-11-26)
• Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198). (2010-09-21)
• Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities. (2008-08-21)
• Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study. (2013-02-04)
• Clinical role of indium-111 antimyosin imaging. (1992-01-30)
• Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors. (1999-11-24)

Authors

• Javier G Blanco
• Can-Lan Sun
• Wendy Landier
• Lu Chen
• Diego Esparza-Duran
• Wendy Leisenring
• Allison Mays
• Debra L Friedman
• Jill P Ginsberg
• Melissa M Hudson
• Joseph P Neglia
• Kevin C Oeffinger
• A Kim Ritchey
• Doojduen Villaluna
• Mary V Relling
• Smita Bhatia

Publication date

2012-04-30

Journal

Journal topics

• Medical Oncology

Language

Eng.

Copyright

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

The State University of New York at Buffalo, Buffalo, NY, USA.

Release reference

J Clin Oncol. 2012 May;30(13):1415-21

Related books

• Books of Age Factors
• Books of Alcohol Oxidoreductases
• Books of Anthracyclines
• Books of Antibiotics, Antineoplastic
• Books of Biotransformation
• Books of Cardiomyopathies
• Books of Case-Control Studies
• Books of Chi-Square Distribution
• Books of Dose-Response Relationship, Drug
• Books of Genetic Predisposition to Disease
• Books of Homozygote
• Books of Logistic Models
• Books of Medical Oncology
• Books of Neoplasms
• Books of Odds Ratio
• Books of Pharmacogenetics
• Books of Phenotype
• Books of Polymorphism, Single Nucleotide
• Books of Risk Assessment
• Books of Risk Factors
• Books of Survivors
• Books of Time Factors
• Books of United States